Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in COPD (ACROSS)
NCT01313494Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2011
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of roflumilast in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Mar 2011; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01313494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313494.